Lifesci Capital Brokers Reduce Earnings Estimates for OVID

Ovid Therapeutics (NASDAQ:OVID) – Equities research analysts at Lifesci Capital lowered their Q1 2026 earnings estimates for shares of Ovid Therapeutics in a report issued on Tuesday, March 24th. Lifesci Capital analyst F. Brisebois now anticipates that the company will earn ($0.11) per share for the quarter, down from their previous estimate of ($0.08). Lifesci Capital has a “Outperform” rating and a $4.00 price target on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. Lifesci Capital also issued estimates for Ovid Therapeutics’ Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.09) EPS and Q4 2026 earnings at ($0.10) EPS.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings results on Wednesday, March 18th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.16. Ovid Therapeutics had a negative return on equity of 23.98% and a negative net margin of 240.11%.The business had revenue of $0.72 million for the quarter, compared to analysts’ expectations of $0.06 million.

Several other analysts also recently issued reports on the company. Wedbush lifted their target price on Ovid Therapeutics from $5.00 to $7.00 and gave the company an “outperform” rating in a research note on Friday, March 20th. Roth Mkm assumed coverage on Ovid Therapeutics in a research note on Thursday, December 11th. They issued a “buy” rating and a $3.00 price target for the company. Wall Street Zen raised shares of Ovid Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ovid Therapeutics in a research report on Thursday, January 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $2.00 target price on shares of Ovid Therapeutics in a report on Monday, December 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $4.43.

Ovid Therapeutics Stock Performance

NASDAQ OVID opened at $2.46 on Thursday. The company has a quick ratio of 8.97, a current ratio of 8.97 and a debt-to-equity ratio of 0.09. Ovid Therapeutics has a twelve month low of $0.24 and a twelve month high of $2.72. The business has a 50-day moving average price of $1.77 and a 200-day moving average price of $1.60. The firm has a market cap of $175.18 million, a price-to-earnings ratio of -7.94 and a beta of 0.25.

Hedge Funds Weigh In On Ovid Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OVID. RA Capital Management L.P. purchased a new position in Ovid Therapeutics during the 4th quarter valued at approximately $17,464,000. Affinity Asset Advisors LLC raised its holdings in shares of Ovid Therapeutics by 169.8% during the 4th quarter. Affinity Asset Advisors LLC now owns 7,150,000 shares of the company’s stock worth $11,654,000 after acquiring an additional 4,500,000 shares in the last quarter. Eventide Asset Management LLC purchased a new stake in shares of Ovid Therapeutics during the 4th quarter worth approximately $6,985,000. ADAR1 Capital Management LLC boosted its position in shares of Ovid Therapeutics by 33,256.7% during the 4th quarter. ADAR1 Capital Management LLC now owns 4,285,000 shares of the company’s stock valued at $6,985,000 after acquiring an additional 4,272,154 shares during the last quarter. Finally, Federated Hermes Inc. bought a new position in shares of Ovid Therapeutics during the 4th quarter valued at approximately $5,307,000. 72.24% of the stock is owned by institutional investors.

About Ovid Therapeutics

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.